{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:48:29Z","timestamp":1788922109004,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002999","name":"Ministerie van Volksgezondheid, Welzijn en Sport","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002999","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.esmoop.2024.104123","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T13:28:21Z","timestamp":1737466101000},"page":"104123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Follow-up after first-Line nivOlumab plus ipilimumab in patients with diffuse pleuRal mesotheliomA: a real-world Dutch cohort study\u2014FLORA"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1986-4947","authenticated-orcid":false,"given":"L.H.","family":"Douma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2906-1732","authenticated-orcid":false,"given":"M.M.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8993-0105","authenticated-orcid":false,"given":"F.","family":"Zwierenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4640-9914","authenticated-orcid":false,"given":"T.M.T.","family":"Zondervan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.I.G.","family":"Buma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Schouwink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.W.","family":"Dumoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Burgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Smesseim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.G.J.V.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.J.","family":"de Gooijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.esmoop.2024.104123_bib1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Popat","year":"2022","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2024.104123_bib2","doi-asserted-by":"crossref","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2024.104123_bib5","first-page":"2531","article-title":"Immunotherapy vs. chemotherapy in subsequent treatment of malignant pleural mesothelioma: which is better?","volume":"12","author":"Guo","year":"2023","journal-title":"J\u00a0Clin Med"},{"issue":"3","key":"10.1016\/j.esmoop.2024.104123_bib6","article-title":"A\u00a0real-world analysis of the use of systemic therapy in malignant pleural mesothelioma and the differential impacts on overall survival by practice pattern","volume":"3","author":"Kerrigan","year":"2022","journal-title":"JTO Clin Res Rep"},{"issue":"3","key":"10.1016\/j.esmoop.2024.104123_bib7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.lungcan.2015.06.018","article-title":"Second line therapy in malignant pleural mesothelioma: a systematic review","volume":"89","author":"Buikhuisen","year":"2015","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2024.104123_bib8","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program","volume":"3","author":"Santoro","year":"2008","journal-title":"J\u00a0Thorac Oncol"},{"issue":"10272","key":"10.1016\/j.esmoop.2024.104123_bib9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.esmoop.2024.104123_bib10","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.104123_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107440","article-title":"Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma","volume":"187","author":"Dumoulin","year":"2024","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2024.104123_bib12","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jtho.2023.11.014","article-title":"Brief report: real-world toxicity and survival of combination immunotherapy in pleural mesothelioma-RIOMeso","volume":"19","author":"McNamee","year":"2024","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 11","key":"10.1016\/j.esmoop.2024.104123_bib13","article-title":"P2.18-04 real-world study on efficacy of first-line nivolumab\u00a0+ ipilimumab in unresectable malignant pleural mesothelioma (ImmunoMeso)","volume":"18","author":"Aguirre","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2024.104123_bib14","doi-asserted-by":"crossref","first-page":"S1133","DOI":"10.1016\/j.annonc.2023.09.973","article-title":"2191P Real-world outcomes of patients with malignant pleural mesothelioma (MPM) treated with combination nivolumab and ipilimumab in the first- or later line setting","volume":"34","author":"Schmid","year":"2023","journal-title":"Ann Oncol"},{"issue":"suppl 11","key":"10.1016\/j.esmoop.2024.104123_bib15","doi-asserted-by":"crossref","first-page":"S383","DOI":"10.1016\/j.jtho.2023.09.678","article-title":"P2.18-05 impact of evolving treatment paradigms on survival outcomes in advanced pleural mesothelioma: a real-world analysis","volume":"18","author":"Wu","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2024.104123_bib16","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jtho.2018.04.034","article-title":"Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (version 1.1)","volume":"13","author":"Armato","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.104123_bib18","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2213-2600(20)30362-3","article-title":"Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial","volume":"9","author":"de Gooijer","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.esmoop.2024.104123_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107866","article-title":"Real-world efficacy and safety of combination nivolumab plus ipilimumab for untreated, unresectable, pleural mesothelioma: the meso-immune (GFPC04-2021) trial","volume":"194","author":"Bylicki","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2024.104123_bib20","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/ajco.14098","article-title":"Real-world outcomes for patients with pleural mesothelioma: a multisite retrospective cohort study","volume":"20","author":"Chow","year":"2024","journal-title":"Asia Pac J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.104123_bib21","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/annonc\/mdi187","article-title":"Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma","volume":"16","author":"Manegold","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.104123_bib22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.rmed.2018.06.026","article-title":"A\u00a0systematic review and meta-analysis of second-line therapies for treatment of mesothelioma","volume":"141","author":"Petrelli","year":"2018","journal-title":"Respir Med"},{"issue":"11","key":"10.1016\/j.esmoop.2024.104123_bib23","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.104123_bib24","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10419","key":"10.1016\/j.esmoop.2024.104123_bib25","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.esmoop.2024.104123_bib26","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S1470-2045(23)00446-1","article-title":"Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study","volume":"24","author":"Douma","year":"2023","journal-title":"Lancet Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924018945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924018945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:46:41Z","timestamp":1740142001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924018945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2059702924018945"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.104123","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Follow-up after first-Line nivOlumab plus ipilimumab in patients with diffuse pleuRal mesotheliomA: a real-world Dutch cohort study\u2014FLORA","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.104123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"104123"}}